Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to "Shanghai Junshi Biosciences Co., Ltd.: Announcement on Progress of Application for Initial Public Offering and Listing of Shares and Suspension of Trading" dated 25 November 2019 published by Shanghai Junshi Biosciences Co., Ltd. (the "Company") on the website of National Equities Exchange and Quotations. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

The trading of the Company's H Shares on The Stock Exchange of Hong Kong Limited will not be affected.

By Order of the Board

Shanghai Junshi Biosciences Co., Ltd.*

Mr. Xiong Jun

Chairman

Shanghai, the PRC, 25 November 2019

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive directors.

• For identification purpose only

		Announcement No.: 2019-157
Stock Code: 833330	Stock Short Name: Junshi Bio-B	Chief Agency Broker: CICC
	Shanghai Junshi Biosciences Co., Ltd.

Announcement on Progress of Application for Initial Public Offering and Listing of Shares

and Suspension of Trading

The Company and all members of the board of directors warrant that the contents of the announcement are true, accurate and complete and that there is no false and misleading statement or material omission herein, and are severally and jointly responsible for the truthfulness, accuracy and completeness of the contents herein.

Shanghai Junshi Biosciences Co., Ltd. (hereinafter referred to as the "Company") proposed the initial public offering of shares and listing. On 25 April 2019, the Company submitted the listing counseling application to the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission and the application was accepted. The listing counseling agency engaged was China International Capital Corporation Limited.

I. Acceptance of Listing Counseling

On 16 September 2019, under the counseling of China International Capital Corporation Limited, the Company has obtained the acceptance from the Shanghai Securities Regulatory Bureau of the China Securities Regulatory Commission in respect of such counseling.

II. The Application Was Accepted by the Shanghai Stock Exchange

The Company has submitted an application for initial public offering of shares and listing on the Sci-techInnovation Board (STAR Market) of the Shanghai Stock Exchange (hereinafter referred to as the "SSE"), and on 26 September 2019, it received Shang Zheng Ke Shen (Shou Li) [2019] No. 159 (上證科審（受理）[2019] 159 號) issued by the SSE, i.e. "Notice on Acceptance of the Application of Shanghai Junshi Biosciences Co., Ltd. for Initial Public Offering of its Shares and Listing on the STAR Market"(《關於受理上海君實生物醫藥科技股份有限公司首次公開發 行股票並在科創板上市申請的通知》), and the application of the Company for initial public offering of its shares and listing on the STAR Market has been officially accepted by the SSE.

Since 25 September 2019, the trading of the shares of the Company has been suspended on National Equities Exchange and Quotations.

On 25 October 2019, the Company received Shang Zheng Ke Shen (Shen He) [2019] No.

667 (上證科審（審核）[2019] 667 號) issued by the SSE, i.e. "Letter of Review and Enquiry on the Application Document of Shanghai Junshi Biosciences Co., Ltd. for Initial Public Offering of its Shares and Listing on the STAR Market"(《關於上海君實生物醫藥科技股份有限公司首次公開 發行股票並在科創板上市申請文件的審核問詢函》). The Company and relevant intermediaries will submit the reply to the letter of enquiry to the SSE in a timely manner within the prescribed period in accordance with the requirements of the above document.

Announcement No.: 2019-157

III. Suspension of Review

Application for suspension of review

According to the requirements of the "Notice on Relevant Issues Concerning the Financial Information Disclosure of the Issuer on the STAR Market"(Shang Zheng Fa [2019] No. 78) (《關 於科創板發行人財務信息披露有關事項的通知》（上證發[2019]78 號）) issued by the SSE, if the financial statements of the company under review has expired, an extension of the validity period should be applied in time in accordance with the "Measures on Registration and Administration of the Initial Public Offering of Shares on the STAR Market (for Trial Implementation)" (《科創板首次公開發行股票註冊管理辦法（試行)》) and "Regulations on Review of the Listing and Issuance of Shares on the STAR Market of the Shanghai Stock Exchange" (《上海證券交易所科創板股票發行上市審核規則》), but the extension should not exceed one month. The financial statements initially submitted for review by the Company are made up to 31 March 2019, and have expired on 30 September 2019. On 27 September 2019, the Company submitted the "Application for the Extension of the Validity Period of the Financial Statements in Application Documents Regarding the Initial Public Offering of Shares and Listing on STAR Market of the Shanghai Stock Exchange of the Shanghai Junshi Biosciences Co., Ltd." (《關於上海君實生物醫藥科技股份有限公司首次公開發行股票並在科創板上市申請文件延 長財務報表有效期的申請》) to the SSE in order to apply for extension of the validity period of the financial statements for one month until 31 October 2019.

Since the auditing work for updating the financial information is still under progress and involves heavy workload, the Company was unable to complete the update on its financial data before 31 October 2019. Therefore, on 31 October 2019, the Company submitted the "Application for the Suspension of Review Process for the Initial Public Offering of Shares and Listing on STAR Market of the Shanghai Stock Exchange of the Shanghai Junshi Biosciences Co., Ltd."《( 上 海君實生物醫藥科技股份有限公司關於首次公開發行股票並在科創板上市中止審核的申請》) to the SSE. Upon completion of the update on its financial data, the Company will promptly apply to the SSE for the resumption of the review process.

At present, the status of the application of the Company for the initial public offering of shares and listing on the STAR Market is "suspended". During the suspension of review process, the Company will continue to conduct various works relating to the IPO, and all related work will not be affected by the suspension of review process.

In accordance with the "Business Rules of the National Equities Exchange and Quotations System (for Trial Implementation)", the trading of the shares of the Company will continue to be suspended on National Equities Exchange and Quotations.

The Company will strictly perform the information disclosure obligations in accordance with the provisions and requirements of laws and regulations based on the progress of related matters, and investors are advised to exercise caution and pay attention to investment risks.

Notice is hereby given.

Shanghai Junshi Biosciences Co., Ltd.

Board of Directors

25 November 2019